There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Springworks Therapeutics (SWTX), Blueprint Medicines (BPMC) and Verastem (VSTM) with bullish sentiments.
Springworks Therapeutics (SWTX)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Springworks Therapeutics, with a price target of $34.00. The company’s shares closed last Monday at $24.52.
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -0.5% and a 41.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.
Springworks Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $34.00.
See today’s analyst top recommended stocks >>
Blueprint Medicines (BPMC)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Blueprint Medicines today and set a price target of $100.00. The company’s shares closed last Monday at $78.48.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 13.1% and a 48.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Cyclacel Pharmaceuticals.
Blueprint Medicines has an analyst consensus of Strong Buy, with a price target consensus of $103.86, representing a 38.8% upside. In a report released today, Cowen & Co. also maintained a Buy rating on the stock.
Verastem (VSTM)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Verastem today and set a price target of $2.50. The company’s shares closed last Monday at $1.32, close to its 52-week low of $0.83.
According to TipRanks.com, Ramakanth has 0 stars on 0-5 star ranking scale with an average return of -7.7% and a 33.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals, ThermoGenesis Holdings, and IntelGenx Technologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Verastem with a $2.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
